The Phase III AVAglio study met its co-primary endpoint
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the phase III AVAglio study of Avastin plus radiation and temozolomide chemotherapy in people with newly diagnosed glioblastoma met its co-primary endpoint of a significant improvement in progression-free survival (PFS).
Bristol-Myers Squibb and AstraZeneca complete expansion of diabetes alliance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.
Lundbeck on track to meet financial expectations and renew its product portfolio
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports first half revenue of DKK 6,829 million, excluding Lexapro® in the US, an increase of 1% compared to the first half of 2011. EBITDA and EBIT, excluding restructuring costs were DKK 1,742 million and DKK 1,264 million respectively, corresponding to an EBITDA margin of 24% and an EBIT margin of 17%.
Luqa Pharmaceuticals and Stratpharma enter into an exclusive agreement
- Details
- Category: Business
Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.
Affinium Pharmaceuticals announces completion of recruitment for Phase 2 clinical trial of AFN-1252
- Details
- Category: Clinical Trials
Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").
Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced an agreement with Servier and its partner XOMA Corporation (Nasdaq: XOMA) to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, XOMA's novel interleukin 1-beta (IL-1β) allosteric modulating antibody.
Bristol-Myers Squibb Foundation awards $1.6 million in grants
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.
More Pharma News ...
- Novartis and University of Pennsylvania form broad-based R&D alliance
- Sanofi second-quarter and first-half sales 2012
- UCB half year results 2012: on track for growth
- Pfizer reports second-quarter 2012 results
- Bayer reports strong business performance in the second quarter of 2012
- Roche reports second positive study of RoACTEMRA
- Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion